(Q35604822)

9 August 2017

1 reference

title

Will mTOR inhibitors make it as cancer drugs? (English)

1 reference

9 August 2017

Charles L Sawyers

1

1 reference

9 August 2017

publication date

1 November 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

5

1 reference

9 August 2017

page(s)

343-348

1 reference

Identification of TOR signaling complexes: more TORC for the cell growth engine

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Clinical development of mammalian target of rapamycin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Targeting epidermal growth factor receptor--are we missing the mark?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

New antitumor substances of natural origin

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Molecular basis of the VHL hereditary cancer syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Akt regulates growth by directly phosphorylating Tsc2

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Oncogenic Ras and Akt Signaling Contribute to Glioblastoma Formation by Differential Recruitment of Existing mRNAs to Polysomes

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Rheb promotes cell growth as a component of the insulin/TOR signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

TOR, a central controller of cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Gene expression profiling identifies molecular subtypes of gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Partitioning the transcriptional program induced by rapamycin among the effectors of the Tor proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Integration of growth factor and nutrient signaling: implications for cancer biology

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900275-7

7 January 2021

10.1016/S1535-6108(03)00275-7

Identifiers

DOI

1 reference

9 August 2017

1 reference